La terapia combinada de metformina y baricitinib atenúa la inflamación en ratas diabéticas inducidas por STZ a través del cruce de la vía AMPK/ JAK- STAT
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Ver abstracta en PubMed
Resumen
Este resumen es generado por máquina.La combinación de metformina y baricitinib en ratas diabéticas redujo la resistencia a la insulina y mejoró la salud hepática y pancreática. Este tratamiento combinado también contrarrestó los efectos negativos del baricitinib en los perfiles lipídicos, ofreciendo beneficios potenciales para los pacientes.
Área De La Ciencia
- Farmacología y Toxicología
- Endocrinología y Metabolismo
- Inmunología
Sus Antecedentes
- La inflamación crónica es un factor clave de las complicaciones de la diabetes.
- El baricitinib (inhibidor de JAK-STAT) y la metformina (activador de AMPK-SIRT, supresor de NF-κB) poseen propiedades antiinflamatorias.
- Se han investigado los efectos combinados de metformina y baricitinib en un modelo de ratas diabéticas.
Objetivo Del Estudio
- Evaluar la eficacia de la administración concomitante de metformina y baricitinib en ratas diabéticas.
- Evaluar el impacto en la resistencia a la insulina, los marcadores inflamatorios y los perfiles lipídicos.
- Determinar si el tratamiento combinado atenúa los efectos adversos del baricitinib.
Principales Métodos
- Diabetes inducida en ratas con estreptozotocina y fructosa.
- Ratas tratadas con dosis variables de baricitinib y una dosis fija de metformina durante un mes.
- Se seleccionó una dosis específica de baricitinib (0,5 mg/ kg) para el tratamiento combinado.
Principales Resultados
- Baricitinib causó pérdida de peso y perfiles lipídicos alterados; ambos fármacos redujeron la NF-κB y la HOMA-IR.
- El tratamiento combinado redujo significativamente el TNF-α y aumentó los niveles de IL-10.
- La terapia combinada aumentó la expresión hepática de NF-κB, SOCS1, SOCS3, AMPK y SIRT-1.
Conclusiones
- La administración concomitante de metformina y baricitinib mejoró la resistencia a la insulina y la histología hepática/ pancreática en ratas diabéticas.
- El tratamiento combinado contrarrestó los efectos adversos del perfil lipídico de baricitinib.
- Los hallazgos son significativos para los pacientes tratados con baricitinib.
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.
Videos de Conceptos Relacionados
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...